Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million

Reuters03-26 20:06

Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million

Aptevo published a full-year earnings release reporting 2025 financial results and a business update.
Net loss was USD 26.0 million and loss from operations was USD 26.3 million.
Research and development expense was USD 14.5 million, up 1.13%, driven by higher mipletamig and employee costs and partly offset by lower ALG.APV-527 costs as the dose escalation trial concluded.
General and administrative expense was USD 11.8 million, up 15.66%, mainly due to higher employee, consulting, and legal costs.
Cash and cash equivalents ended 2025 at USD 21.6 million, and management said current resources are expected to fund operations into Q4 2026 while a USD 60.0 million equity line is expected, if fully utilized alongside current resources, to support operations into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622852089?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622852089","market":"fut","top_or_hot":-1,"title":"Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aptevo published a full-year earnings release reporting 2025 financial results and a business update.\n        </li>\n<li>\n          Net loss was USD 26.0 million and loss from operations was USD 26.3 million.\n        </li>\n<li>\n          Research and development expense was USD 14.5 million, up 1.13%, driven by higher mipletamig and employee costs and partly offset by lower ALG.APV-527 costs as the dose escalation trial concluded.\n        </li>\n<li>\n          General and administrative expense was USD 11.8 million, up 15.66%, mainly due to higher employee, consulting, and legal costs.\n        </li>\n<li>\n          Cash and cash equivalents ended 2025 at USD 21.6 million, and management said current resources are expected to fund operations into Q4 2026 while a USD 60.0 million equity line is expected, if fully utilized alongside current resources, to support operations into 2029.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Aptevo published a full-year earnings release reporting 2025 financial results and a business update.\n        </li>\n<li>\n          Net loss was USD 26.0 million and loss from operations was USD 26.3 million.\n        </li>\n<li>\n          Research and development expense was USD 14.5 million, up 1.13%, driven by higher mipletamig and employee costs and partly offset by lower ALG.APV-527 costs as the dose escalation trial concluded.\n        </li>\n<li>\n          General and administrative expense was USD 11.8 million, up 15.66%, mainly due to higher employee, consulting, and legal costs.\n        </li>\n<li>\n          Cash and cash equivalents ended 2025 at USD 21.6 million, and management said current resources are expected to fund operations into Q4 2026 while a USD 60.0 million equity line is expected, if fully utilized alongside current resources, to support operations into 2029.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a> published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9WHLGl:1","article_id":"2622852089","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622852089","pubTimestamp":1774526819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptevo published a full-year earnings release reporting 2025 financial results and a business update.Net loss was USD 26.0 million and loss from operations was USD 26.3 million.Research and development expense was USD 14.5 million, up 1.13%, driven by higher mipletamig and employee costs and partly offset by lower ALG.APV-527 costs as the dose escalation trial concluded.General and administrative expense was USD 11.8 million, up 15.66%, mainly due to higher employee, consulting, and legal costs.Cash and cash equivalents ended 2025 at USD 21.6 million, and management said current resources are expected to fund operations into Q4 2026 while a USD 60.0 million equity line is expected, if fully utilized alongside current resources, to support operations into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APVO":"Aptevo Therapeutics Inc."},"translate_title":"Aptevo Therapeutics 2025财年每股亏损收窄至87.27美元；现金及现金等价物跃升148%至2200万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":0.9},"content_text":"Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million\n    \n\n\n          Aptevo published a full-year earnings release reporting 2025 financial results and a business update.\n        \n\n          Net loss was USD 26.0 million and loss from operations was USD 26.3 million.\n        \n\n          Research and development expense was USD 14.5 million, up 1.13%, driven by higher mipletamig and employee costs and partly offset by lower ALG.APV-527 costs as the dose escalation trial concluded.\n        \n\n          General and administrative expense was USD 11.8 million, up 15.66%, mainly due to higher employee, consulting, and legal costs.\n        \n\n          Cash and cash equivalents ended 2025 at USD 21.6 million, and management said current resources are expected to fund operations into Q4 2026 while a USD 60.0 million equity line is expected, if fully utilized alongside current resources, to support operations into 2029.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622852089","isCrawlerRequest":true}